Viralgen Vector Core News Today

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number...

Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).

Bayer shares were up on Tuesday morning on the Frankfurt Stock Exchange, with the pharmaceutical group announcing the inclusion of its first patient in a clinical study important for the future of its...

GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy 

Viralgen Vector Core welcomes back Andy Holt in new role as Chief Commercial OfficerSAN SEBASTIAN, SPAIN / ACCESSWIRE / October 19, 2023 / Viralgen Vector Core (Viralgen) is pleased to welcome back their previous Executive Vice President of Commercial ...

Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to manufacture...

Gene therapy for ultra-rare diseases afflicting children stand to significantly advance with a ground-breaking launch of Social Purpose Corporation, Elpida Tx.

/PRNewswire/ -- Viralgen Vector Core (Viralgen), an independently operated subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio), and a member of the Bayer...